Роль апиксабана в лечении венозных тромбоэмболических осложнений у больных с активным раком [PDF]
, 2020 The relationship of venous thromboembolic complications (VTEC) to cancer is well known. Modern recommendations for the treatment of VTEC in patients with cancer suggest treatment with subcutaneous injections of LMWH in the first 6 months.
E. Panchenko P. +1 more
core +4 more sources
Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease [PDF]
, 2021 Due to the population aging and the accumulation of concomitant diseases, the prevalence of atrial fibrillation (AF) as the most common arrhythmia is increasing. On the other hand, 14% of the population has chronic kidney disease (CKD).
N. Sh. Zagidullin, P. A. Davtyan
core +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj +1 more source
Aspects of anticoagulant therapy in venous thromboembolism, pulmonary embolism. Focus on elderly patients [PDF]
, 2022 The prevalence and mortality due to venous thromboembolism (VTE) occupies a leading position among the population throughout the world. The incidence and severity of VTE increases the older the patient.
D. V. Puzenko, M. V. Romanova
core +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Background. For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (such as warfarin), antiplatelet therapy
A. V. Rudakova, V. A. Parfenov
doaj +1 more source
Prognosis and prevention of cardioembolic stroke in patients with atrial fibrillation
Медицинский совет, 2013 The article is a review of literature on the prognosis and prevention of stroke in patients with atrial fibrillation (AF). It is noted that the simple CHA2DS2-VASc calculator is a good predictor of the risk of stroke in AF.
V. А. Parfyonov, S. V. Verbitskaya
doaj +1 more source
Characteristics of atrial fibrillation in older people [PDF]
, 2018 The prevalence of atrial fibrillation (AF) increases with aging. It is associated with serious health consequences. The degenerative changes and the comorbidities result in anatomical substrate for this arrhythmia.
Chalakova, Tatyana, Todorova, Vesela
core +2 more sources
АПИКСАБАН В ЛЕЧЕНИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: РАНДОМИЗИРОВАННЫЕ ИССЛЕДОВАНИЯ И ПОВСЕДНЕВНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА [PDF]
, 2017 Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
E. Panchenko P. +3 more
core +2 more sources
Механическая поддержка кровообращения у детей: патофизиология педиатрического гемостаза и алгоритмы послеоперационного ведения [PDF]
, 2023 Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric ...
D. V. Ryabtsev +7 more
core +2 more sources
NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
Атеротромбоз, 2015 About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF).
E. P. Panchenko
doaj +1 more source